Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer 's (PFE -0.28%) management team is confident in its 2025 opportunities. *Stock prices used were the afternoon prices of May 20, 2025. The video was published on May 22, 2025.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

These might not immediately impact its stock performance, but together with its pipeline goals, they could eventually lead to much stronger returns. Pfizer's decision to license SSGJ-707 doesn't ...

Pfizer (PFE) is currently under significant scrutiny due to a study linking its product, Depo-Provera, to increased health risks, and an associated Multi-District Litigation could have influenced its ...

So far this year, Pfizer’s stock has declined 13.7% compared with a decrease of 3.6% for the industry. Pfizer Stock Performance Image Source: Zacks Investment Research ...

For Pfizer, the consensus sales estimate for the current quarter of $13.56 billion indicates a year-over-year change of +2.1%. For the current and next fiscal years, $63.2 billion and $62.88 ...